• TG003 and the Future of Alternative Splicing in Oncology

  2026-05-15

  This thought-leadership article explores the mechanistic and translational landscape of Cdc2-like kinase (Clk) inhibition with TG003, focusing on its impact in platinum-resistant ovarian cancer, alternative splicing modulation, and emerging exon-skipping therapies. By integrating recent clinical evidence and competitive product intelligence, it offers strategic guidance for translational researchers aiming to bridge molecular insight with therapeutic innovation.

• Metabolomics Reveals Resistance Mechanisms in Carbapenemase-

  2026-05-15

  A recent study harnessed LC-MS/MS metabolomics to identify metabolic biomarkers distinguishing carbapenemase-producing Enterobacterales (CPE) from non-CPE strains. This approach enables rapid detection of resistant phenotypes and provides mechanistic insight into the metabolic pathways underpinning carbapenem resistance.

• SC 79: Applied Akt Activator Workflows for Neuroprotection

  2026-05-14

  SC 79 stands apart as a cytosol-specific Akt activator, enabling reproducible neuroprotection and precision in Akt signaling pathway research. This article delivers workflow-driven protocols, troubleshooting strategies, and practical insights for maximizing the impact of SC 79 in ischemic stroke and cell death prevention models.

• T7 RNA Polymerase: Optimizing In Vitro Transcription Workflo

  2026-05-14

  APExBIO’s T7 RNA Polymerase is a recombinant enzyme expressed in E. coli, powering high-yield, high-specificity in vitro transcription for RNA therapeutics and molecular biology. Discover advanced workflow strategies, troubleshooting tips, and lessons from groundbreaking inhaled RNA cancer immunotherapy research.

• Spider Toxin v-Agatoxin-IVA: Revising Neuronal Ca Channel Se

  2026-05-13

  Sidach and Mintz (2000) demonstrate that v-Agatoxin-IVA, long regarded as a selective P-type calcium channel blocker, also inhibits N-type channels at higher concentrations. This nuanced pharmacological profile refines the classification of neuronal calcium channel subtypes and impacts the use of channel-specific antagonists in neurophysiology and neurodegenerative disease model research.

• Lactate-GPR81-FARP1-Rac1 Axis Enables Insulin-Independent Gl

  2026-05-13

  This study reveals that lactate, via activation of GPR81 and downstream FARP1-Rac1 signaling, promotes insulin-independent glucose uptake in skeletal muscle. The findings uncover a metabolite-driven mechanism for GLUT4 translocation and offer new avenues for metabolic disease intervention beyond classical insulin pathways.

• Dual Glutamate Receptor Blockade Mitigates Soman-Induced Neu

  2026-05-12

  The referenced study demonstrates that targeting both AMPA and NMDA receptors with IEM-1925 provides robust protection against status epilepticus, neuronal degeneration, and cognitive deficits following soman exposure in a rat model. These findings highlight the translational promise of dual glutamate receptor antagonism as a neuroprotective strategy in acute organophosphate poisoning.

• CIP2A Drives PKM2 Tetramerization and OXPHOS in NSCLC Metabo

  2026-05-12

  This study reveals that CIP2A, an oncoprotein, promotes oxidative phosphorylation in non-small cell lung cancer (NSCLC) by inducing tetramer formation of PKM2 and redirecting its mitochondrial function. These findings challenge classical views on cancer cell metabolism and highlight new therapeutic strategies targeting CIP2A and glycolysis.

• Nilotinib (AMN-107): Optimizing Kinase Signaling Assays

  2026-05-11

  Nilotinib (AMN-107) stands apart in chronic myeloid leukemia and gastrointestinal stromal tumor research by combining exquisite BCR-ABL and KIT mutant selectivity with robust, reproducible performance. This article bridges recent mechanistic advances in ribotoxic stress signaling and kinase pathway analysis, delivering actionable workflows and troubleshooting strategies for leveraging APExBIO's Nilotinib in precision cancer research.

• Cy3 Goat Anti-Human IgG (H+L) Antibody: Data-Driven Lab Solu

  2026-05-11

  Discover how the Cy3 Goat Anti-Human IgG (H+L) Antibody (SKU K1208) addresses common challenges in immunofluorescence, immunohistochemistry, flow cytometry, and ELISA. This article presents scenario-based, evidence-backed guidance for bench scientists seeking reproducible, high-sensitivity human IgG detection, with practical protocol insights and vendor selection advice.

• EZ Cap™ Firefly Luciferase mRNA: Optimizing Reporter Assays

  2026-05-10

  EZ Cap™ Firefly Luciferase mRNA empowers researchers to achieve highly sensitive, sustained bioluminescent reporting for gene regulation and mRNA delivery studies. This guide delivers actionable workflows, troubleshooting strategies, and the latest translational insights to maximize signal fidelity and reproducibility in both in vitro and in vivo models.

• Sulfamonomethoxine: Applied Workflows in Veterinary & Aquati

  2026-05-09

  Sulfamonomethoxine (SMM) is a trusted veterinary and aquaculture antibiotic with robust performance in both antimicrobial and environmental toxicity studies. This article delivers detailed protocols, troubleshooting strategies, and comparative insights to help researchers maximize reproducibility and scientific impact with APExBIO’s SMM.

• Improving In Vitro Evaluation of Cancer Drug Responses

  2026-05-09

  Schwartz's dissertation introduces a nuanced framework for differentiating between drug-induced proliferative arrest and cell death in cancer cell models. These insights enhance the precision of in vitro drug response assessments and highlight the complexity of interpreting anti-cancer compound efficacy.

• RepSox (ALK5 Inhibitor): Optimizing iPSC Platelet Production

  2026-05-08

  RepSox, a potent and selective ALK5 inhibitor, is redefining induced pluripotent stem cell (iPSC) workflows for efficient and cost-effective platelet production. By integrating RepSox into advanced protocols, researchers boost yield, accelerate differentiation, and streamline cell therapy applications.

• Berberine Counters Estrogen Deficiency Bone Loss via Tuft Ce

  2026-05-07

  This study demonstrates that berberine ameliorates estrogen deficiency-induced bone loss by promoting intestinal tuft cell expansion, a process driven by butyrate-GPR41 signaling. These findings significantly advance understanding of the gut-bone axis and suggest new strategies for postmenopausal osteoporosis management.

451 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page